Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | €685.24B | 85.9x | 1.27 | €759.50 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | €684.56B | 86x | 1.27 | €761.60 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | €458.27B | 36.4x | 1.32 | €103.70 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | €458.27B | 36.4x | 1.32 | €104.48 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | €355.38B | 25.4x | -0.47 | €147.16 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | €354.47B | 25.3x | -0.47 | €147.52 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | €306.30B | 63.3x | -2.97 | €172 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | €243.08B | 21x | 0.13 | €96.70 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €242.74B | 21x | 0.13 | €96.20 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | €232.38B | 20.4x | -5.94 | €34.22 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | €196.85B | 31.8x | 3.3 | €127.55 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | €196.85B | 31.8x | 3.3 | €64.50 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | €196.85B | 31.8x | 3.3 | €127.80 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Xetra | Healthcare | Pharmaceuticals | €142.90B | 35.3x | -0.81 | €265.60 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Frankfurt | Healthcare | Pharmaceuticals | €142.32B | 35.3x | -0.81 | €265.30 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Xetra | Healthcare | Pharmaceuticals | €139.68B | 34.3x | -0.58 | €24.63 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Frankfurt | Healthcare | Pharmaceuticals | €139.35B | 34.4x | -0.58 | €24.64 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Frankfurt | Healthcare | Pharmaceuticals | €115.69B | -16.7x | 0.09 | €56.39 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers | Xetra | Healthcare | Pharmaceuticals | €115.03B | -16.5x | 0.09 | €56.45 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi SA | Xetra | Healthcare | Pharmaceuticals | €114.74B | 25.5x | -0.51 | €91.43 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Frankfurt | Healthcare | Pharmaceuticals | €114.74B | 25.5x | -0.51 | €91.60 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Frankfurt | Healthcare | Pharmaceuticals | €111.96B | 930.5x | -9.35 | €88.82 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Xetra | Healthcare | Pharmaceuticals | €111.45B | 923.2x | -9.35 | €89.31 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Chugai Pharma | Frankfurt | Healthcare | Pharmaceuticals | €69.31B | 27.9x | 1.88 | €39.48 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Xetra | Healthcare | Pharmaceuticals | €65.98B | 21.8x | -0.37 | €16.30 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Frankfurt | Healthcare | Pharmaceuticals | €65.98B | 21.8x | -0.37 | €16.39 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK | Frankfurt | Healthcare | Pharmaceuticals | €65.98B | 21.8x | -0.37 | €32.40 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | €61.67B | 22.9x | -3.24 | €141.85 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.4% Upside | Upgrade to Pro+ | |
Merck KGaA | Frankfurt | Healthcare | Pharmaceuticals | €61.67B | 22.9x | -3.24 | €141.35 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.2% Upside | Upgrade to Pro+ | |
Daiichi Sankyo | Frankfurt | Healthcare | Pharmaceuticals | €58.72B | 37.1x | 0.51 | €31.50 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |